Osteoporosis: Current Concepts

Ibrahim Akkawi1  Hassan Zmerly1

1 Orthopaedics and Traumatology Unit, Villa Erbosa Hospital, Bologna, Italy

Joints 2018;6:122–127.

Abstract

Osteoporosis is a worldwide disease characterized by reduction of bone mass and alteration of bone architecture resulting in increased bone fragility and increased fracture risk. Causes of osteoporosis include increasing age, female sex, postmenopausal status, hypergonadism or premature ovarian failure, low body mass index, ethnic background, rheumatoid arthritis, low bone mineral density (BMD), vitamin D deficiency, low calcium intake, hyperkyphosis, current smoking, alcohol abuse, immobilization, and long-term use of certain medications. The diagnosis of osteoporosis is established by measurement of BMD of the hip and spine using dual energy X-ray absorptiometry. According to the World Health Organization criteria, osteoporosis is defined as a BMD that lies 2.5 standard deviation or more below the average value for young healthy women. Bone turnover biomarker detection may be useful in monitoring osteoporosis treatment and assessing fracture risk but not for diagnosis of osteoporosis. Management of osteoporosis consists of nonpharmacological interventions, which are recommended for all subjects, and pharmacological therapy in all postmenopausal women who have had an osteoporotic fracture or have BMD values consistent with osteoporosis.

Keywords

► osteoporosis
► DEXA
► bone mineral density
► anabolic agents
► antiresorptive agents

Introduction

Osteoporosis is a worldwide disease characterized by reduction of bone mass and alteration of bone architecture resulting in increased bone fragility and increased fracture risk.1–4 The prevalence of osteoporosis is expected to increase significantly in the future because of aging of the population.5,6 Osteoporosis mainly occurs in postmenopausal women and elderly men.7

Approximately 200 million people suffer from osteoporosis and approximately 8.9 million fractures are caused by osteoporotic fracture.5 These fractures occur mainly at the hip, vertebrae, and distal forearm7 and are associated with significant morbidity, mortality, and reduced quality of life, attributed not only to the fracture itself but also to the high prevalence of comorbidities in this population of patients.6,7 Moreover, osteoporosis represents a major concern of the health care systems because of its growing economic burden.5 In the United States, costs related to osteoporosis fractures were estimated at $13.8 billion.6

Definition

According to the National Institutes of Health Consensus Development Panel on Osteoporosis,9 osteoporosis is defined as “a skeletal disorder characterized by compromised bone strength leading to an increased risk of fracture.” Moreover, according to the World Health Organization (WHO) criteria, osteoporosis is defined as a bone mineral density (BMD) that lies 2.5 standard deviation (SD) or more below the average value for young healthy women (a T-score of < −2.5 SD).10

Osteoporosis can be subdivided into primary osteoporosis, which includes postmenopausal osteoporosis (type I) and senile osteoporosis (type II), and secondary osteoporosis, which has a clearly definable etiologic mechanism such as malabsorption, medications such as glucocorticoids, and some diseases such as hyperparathyroidism.11,12

Risk Factors

Causes of osteoporosis include increasing age, female sex, postmenopausal status, hypergonadism or premature
ovarian failure, low body mass index, ethnic background (white persons are at higher risk than black persons), rheumatoid arthritis (RA), low BMD, vitamin D deficiency, low calcium intake, hyperkphysis, current smoking, alcohol abuse, immobilization, and long-term use of certain medications, such as glucocorticoids, anticoagulants, anticonvulsants, aromatase inhibitors, cancer chemotherapeutic drugs, and gonadotropin-releasing hormone agonists.2,4,13,14

Diagnosis

Osteoporosis is a silent disease without obvious symptoms and evidence until a fracture occurs.3 Thus, screening by dual energy X-ray absorptiometry (DEXA) is important to obtain an early diagnosis and to avoid fractures.2 All women aged 65 years or older and men aged 70 years or older, postmenopausal women with medical causes of bone loss (e.g., steroid use) regardless of age, postmenopausal women aged 50 years or older with additional risk factors for fracture (e.g., current smoker, RA, history of hip fracture in a parent), and postmenopausal women with a fragility fracture should be screened for osteoporosis by BMD measurement at the hip and lumbar spine as recommended by the U.S. Preventive Services Task Force (USPSTF), the National Osteoporosis Foundation, and by other guidelines.10–12,15

BMD is mainly described as T-score, which represents the number of SD by which the BMD in an individual differs from the mean value expected in young healthy individuals.6 Based on the report of the WHO, BMD with a T-score above 1 SD is classified as normal BMD, a T-score between −1.0 and −2.5 SD is classified as osteopenia, and a T-score below −2.5 SD is defined as osteoporosis.10 According to Gourlay et al,16 rescreening intervals are 15 years for those with normal BMD (T-score ≥ −1.0) or mild osteopenia (T-score < −1.0 and > −1.5), 5 years for those with moderate osteopenia (T-score < −1.5 and > −2.0), and 1 year for those with advanced osteopenia (T-score < −2.0 and > −2.5).

Bone Turnover Biomarkers

Bone turnover biomarkers (BTMs) are produced from the bone remodeling process and can be measured in urine or serum. They are classified as markers of bone formation (total alkaline phosphatase [total ALP], bone-specific alkaline phosphatase [B-ALP], osteocalcin [OC], procollagen type I N-terminal propeptide [P1NP], and procollagen type I C-terminal propeptide [P1CP]) and markers of bone resorption (hydroxyproline [HYP], deoxypyridinoline [DPD], pyridinoline, tartrate-resistant acid phosphatase 5b [TRAP 5b], carboxy-terminal cross-linked telopeptide of type 1 collagen [CTX-1], and amino-terminal cross-linked telopeptide of type 1 collagen [NTX-1]).5,17

The total ALP concentration represents the sum of ALP isoenzymes from bones, liver, and intestine. In adults with normal liver function, almost 50% of ALP activity in serum is derived from bone and is produced by osteoblasts during bone formation. Therefore, measurement of total ALP activity lacks sensitivity and specificity in osteoporosis.17 B-ALP is more specific for bone and, therefore, more sensitive in detecting the small changes in bone formation seen in osteoporosis.17,18 OC is considered a specific biomarker of osteoblast function for the evaluation of bone formation rate in osteoporosis.5,17 The concentration of P1NP and P1CP in serum reflects bone formation rate,17 as they are produced during conversion of procollagen type I to collagen type I.19 Kučkalić-Selimović et al19 found that P1NP is significantly higher in postmenopausal females with osteoporosis compared with postmenopausal females with preserved bone mass, but its low specificity does not warrant its utility in diagnosing osteoporosis.

HYP is produced from the degradation of bone collagen during bone resorption.17 Since HYP can be found in other tissues such as skin and cartilage, it is considered a non-specific marker of bone resorption.5 Pyridinoline and DPD are released during breakdown of bone and cartilage; their concentration in urine are more sensitive and specific markers of bone resorption than urinary HYP.17 TRAP 5b is normally secreted by osteoclasts and is considered a specific and high sensitive biomarker of bone resorption.20 CTX-1 and NTX-1 are released during collagen degradation. CTX-1 is a specific and sensitive biomarker of bone resorption but is influenced by food intake, thus blood withdrawal must take place in the fasting state in the morning.21 On the contrary, urinary NTX-1 is not affected by food intake.17

According to the European guidance for the diagnosis and management of osteoporosis in postmenopausal women, the most informative ones for the investigation of osteoporosis are OC and P1NP for assessing bone formation and CTX1 to assess bone resorption.22

According to the current guidelines on osteoporosis management, BTM cannot diagnose osteoporosis, but changes in BTMs may be useful in monitoring osteoporosis treatment to confirm the efficacy of treatment and treatment adherence.11,23 Furthermore, the measurement of BTMs in women with a low BMD can improve the specificity of assessment of fracture risk.21–24

Treatment

The primary goal of osteoporosis therapy is to reduce the risk of fracture.25 Treatment and prevention strategies of osteoporosis and osteoporotic fractures include fall avoidance by correcting decreased visual acuity, reducing consumption of medication that alters alertness and balance, reducing fall hazards in the home (slippery floors, obstacles, insufficient light), practicing physical activity to improve muscle strength, balance, and maintaining bone mass, the avoidance of cigarette smoking and excessive alcohol intake, and adequate dietary intake of protein, calcium, and vitamin D.11,12,26 In women, the recommended daily allowance (RDA) for calcium is 1,000 mg/d for age range of 19 to 50 years and increases to 1,200 mg/d for older than 50 years; in men, the RDA of calcium is 1,000 mg/d for age range of 19 to 70 years and increases to 1,200 mg/d for older than 70 years. The RDA for vitamin D is 600 IU/d for men and women aged 19 to 70 years and increases to 800 IU/d for those older than
Bisphosphonates

BPs are the first option for the treatment of osteoporosis. These drugs, such as alendronate, risedronate, ibandronate, etidronate, clodronate, and zoledronic acid, are potent inhibitors of bone resorption and mainly increase the BMD of trabecular bones.\(^\text{3,26}\) It has been shown that BPs reduce vertebral, nonvertebral, and hip fractures compared with placebo in postmenopausal osteoporotic women.\(^\text{4}\)

Oral BPs are associated with mild upper gastrointestinal symptoms such as dysphagia and esophagitis.\(^\text{4,12,26}\) Moreover, BPs are associated with atypical femoral fractures (AFF), and osteonecrosis of the jaw (ONJ), albeit these events are rare (5.9/100,000 person-years and 2/100,000 patient-years, respectively).\(^\text{11,27,28}\) Park-Wyllie et al.\(^\text{29}\) found that among older women, treatment with a BP for more than 5 years was associated with an increased risk of AFF. Galis et al.\(^\text{30}\) observed that the risk of ONJ development is increased by several factors, such as duration of BP therapy, administration route of BP, type of BP, invasive dental procedures or dental prostheses, oncological disease, Caucasian origin, and multiple myeloma. Other adverse effects include hypocalcemia, influenza-like symptoms, uveitis, and episcleritis.\(^\text{4}\) BPs are contraindicated in patients with low serum calcium and severe renal impairment (creatinine clearance below 30–35 mL).\(^\text{12}\)

After 3 years of treatment with intravenous zoledronic acid or 5 years with oral BP, a treatment break should be considered as suggested by the American Society for Bone and Mineral Research, USPSTF, and the American College of Physicians (ACP), whereas if there are characteristics indicative of high fracture risk, such as old age, low hip T-score or high fracture risk score, previous major osteoporotic fractures, or fractures on therapy, it is recommended to continue the treatment with BPs up to 10 years.\(^\text{4,11}\)

Denosumab

Receptor activator of nuclear factor-kappa B ligand (RANKL) is expressed on the membrane of osteoblastic cells and binds to its receptor, RANK, on the surface of osteoclasts, which is essential for osteoclast formation, activity, and survival. Denosumab is a human monoclonal antibody that binds RANKL and prevents it from combining with RANK on the osteoclast membrane, thus inhibiting its action, favoring bone formation over bone resorption, and increasing bone mass and strength in both trabecular and cortical bone, thereby reducing radiographic vertebral, nonvertebral, and hip fractures in postmenopausal osteoporotic women.\(^\text{4,3,12}\)

Similarly to BP, denosumab therapy is associated with mild upper gastrointestinal symptoms, AFF and ONJ; moreover, it is associated with increased risk for infection, rash, and/or eczema.\(^\text{3}\) Therefore, in patients considered at low risk of fracture after 5 years of treatment, discontinuation of denosumab is recommended, whereas in patients with a low BMD or multiple vertebral fractures or a high fracture risk score, it is advisable to continue treatment with denosumab for up to 10 years and consolidate with a single infusion of zoledronic acid.\(^\text{32}\)

Strontium Ranelate

Strontium ranelate (Sr RAN) increases the osteoblast differentiation while osteoclast formation is inhibited simultaneously, thus Sr RAN significantly improves bone mass and quality, and increases bone strength; therefore, it remarkably reduces the risk of vertebral, nonvertebral, and hip fractures in a wide range of postmenopausal women with documented osteoporosis.\(^\text{33}\)

The most common reported adverse effects of Sr RAN are cardiovascular events, venous thromboembolism, myocardial infarction, gastrointestinal discomfort, and signs and symptoms of nervous system such as headache, seizure, and memory loss.\(^\text{34}\) Sr RAN is not recommended for patients with severe renal impairment (creatinine clearance below 30 ml/min), patients with a previous history of thrombophlebitis, and patients with established current or previous history of ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease, and uncontrolled hypertension.\(^\text{11,26}\)

The Italian guidelines for the diagnosis, prevention, and management of osteoporosis stated that the use of Sr RAN must be restricted to the treatment of severe osteoporosis in postmenopausal women or in adult men with high risk of fracture for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible.\(^\text{11}\)

Estrogen Replacement Therapy

Since menopause is characterized by estrogen deficiency that results in bone loss, it has been suggested that the use of ERT is effective for prevention of osteoporosis in postmenopausal women, but it is not recommended as the first-line preventive treatment of osteoporosis.\(^\text{13}\) ERT is associated with an increased risk of coronary heart disease, breast cancer, stroke, and dementia.\(^\text{11,26}\)
Selective Estrogen Receptor Modulator
Raloxifene is the only SERM widely available for the prevention and treatment of postmenopausal osteoporosis.\textsuperscript{26} It reduces the risk of vertebral fractures in postmenopausal women with osteoporosis but has no effect on the risk for nonvertebral fractures. Therefore, it is not a first-line agent for postmenopausal osteoporosis. Moreover, the long-term use of raloxifene increases the risk of venous thromboembolic events.\textsuperscript{2}

ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women.\textsuperscript{4}

Calcitonin
Calcitonin inhibits osteoclastic bone resorption.\textsuperscript{26} The use of a nasal spray formulation of salmon calcitonin to treat osteoporosis is associated with an increased risk of cancer. Hence, salmon calcitonin has been withdrawn from the market in Europe and Canada. Although it is available in the United States for treating osteoporosis (but not for prevention), the Food and Drug Administration Advisory Committee has not recommended it.\textsuperscript{12,35} Drug-related adverse effects include nausea, local inflammation, and flushing of the face or hands when calcitonin is given as an injection, and local nasal irritation with the nasal spray formulation.\textsuperscript{12}

Teriparatide
Teriparatide is a peptide corresponding to the 34 N-terminal amino acids of parathyroid hormone (PTH). Candidates for teriparatide treatment include patients with contraindications to oral and intravenous BPs, those who have had a major osteoporotic fracture while receiving oral BPs, and treatment-naive persons with very low BMD T-scores ($\leq -3.5$).\textsuperscript{2} It is contraindicated in conditions characterized by abnormally increased bone turnover (e.g., preexisting hypercalcemia, metabolic bone diseases other than primary osteoporosis, unexplained elevation of ALP, severe renal impairment, prior skeletal irradiation, or patients with skeletal malignancies or bone metastasis).\textsuperscript{12,26}

Teriparatide treatment reduces vertebral and nonvertebral fractures among women with postmenopausal osteoporosis.\textsuperscript{4} Treatment with teriparatide is characterized by an early period dominated by bone formation that lasts for 6 to 9 months and is referred to as the anabolic window. Then, bone resorption increases and mitigates the overall bone anabolic effect.\textsuperscript{36}

Teriparatide treatment is associated with mild upper gastrointestinal symptoms, nausea, pain in the limbs, dizziness, headache, hypercalcemia, hypercalciuria, hyperuricemia, and hypotension.\textsuperscript{4,26} Moreover, the use of teriparatide is limited to 2 years in any life span, and this is because of the development of osteosarcoma in preclinical animal studies.\textsuperscript{3}

Romosozumab
Romosozumab is another anabolic drug, which is still under clinical development. It is an antibody of sclerostin that represent an important component of the Wnt signaling pathway, a well-known metabolic route to drive osteoblast proliferation. Thus, it increases bone formation, bone mass, and strength at various skeletal sites.\textsuperscript{7} Romosozumab has been evaluated in a double-blind study at a monthly dose of 210 mg versus placebo in 7,180 postmenopausal women who had a T-score of $-2.5$ to $-3.5$ at the total hip or femoral neck. At 12 months, new vertebral fractures had occurred in 16 of 3,321 patients (0.5%) in the romosozumab group, as compared with 59 of 3,322 (1.8%) in the placebo group (representing a 73% lower risk with romosozumab). Clinical fractures had occurred in 58 of 3,589 patients (1.6%) in the romosozumab group, as compared with 90 of 3,591 (2.5%) in the placebo group (a 36% lower risk with romosozumab). Nonvertebral fractures had occurred in 56 of 3,589 patients (1.6%) in the romosozumab group and in 75 of 3,591 (2.1%) in the placebo group.\textsuperscript{37}

Combined Treatments
Osteoporosis treatments are currently limited to the use of a single drug at a fixed dose,\textsuperscript{38} while combination pharmacotherapy is not recommended.\textsuperscript{5} Combination of more than two antiresorptive agents have demonstrated very limited additive effects on bone mass.\textsuperscript{39} Similarly, combination of PTH and teriparatide with BPs or SERM does not have an overall superior effect on BMD compared with monotherapy.\textsuperscript{40,41} On the contrary, it has been shown that combined therapy of teriparatide with denosumab or zoledronate may be an effective treatment option for patients who do not respond to teriparatide monotherapy.\textsuperscript{25} A study found that the addition of alendronate to teriparatide after the first 9 months of teriparatide treatment contributed to a reopening of the anabolic window and led to a return of bone resorption to levels comparable at the initiation of teriparatide therapy, whereas bone formation was less suppressed and remained elevated.\textsuperscript{36} Furthermore, the recent denosumab and teriparatide administration study indicated that the combination of denosumab and teriparatide produced a more prominent effect on increasing BMD and decreasing fracture risk than each drug did alone.\textsuperscript{38} It also indicated that teriparatide treatment after denosumab was associated with transient bone loss in lumbar spine and proximal femur and with prolonged BMD decrease in distal radius, while teriparatide followed by denosumab continuously increased the BMD of lumbar spine and proximal femur. The authors concluded that it is necessary to consider the timing of teriparatide use, as well as the order of sequential use of teriparatide, in the long-term management of patients with osteoporosis.\textsuperscript{38} Finally, since discontinuation of estrogens, SERMs, denosumab, or teriparatide therapy is associated with a rapid loss of their effects on BMD and BTMs over 1 to 2 years, a follow-up treatment with BP should be considered to reduce or prevent the rebound increase in bone turnover.\textsuperscript{38}

Conclusion
Osteoporosis is a skeletal disorder characterized by compromised bone strength leading to an increased risk of fracture.
It is defined as a BMD that lies 2.5 SD or more below the
definition of healthy women, measured with DEXA. According to the current
guidelines on osteoporosis management, BTMs cannot diagnose osteoporosis, but
changes in BTMs may be useful in monitoring osteoporosis
treatment to confirm the efficacy of treatment and treat-
ment adherence and can improve the specificity of assess-
ment of fracture risk. All postmenopausal women should be
encouraged to maintain a healthy weight; to obtain adequate
calcium, vitamin D, and protein intake; to participate in
appropriate exercise; to avoid excessive alcohol consump-
tion and smoking; and to utilize measures that prevent falls.
Finally, drug therapy is recommended in all postmenopausal
women who have a history of osteoporotic vertebral or hip
fracture, in those who have BMD values consistent with
osteoporosis, and in those who have T-scores from −1.0 to
−2.5 and a 10-year risk of major osteoporotic fracture.

Conflict of Interest
None.

References
1 Dunnwind T, Dwortsin EP, Smeets HM, et al. Economic conse-
quences and potentially preventable costs related to osteoporosis
in the Netherlands. Value Health 2017;20(06):762–768
2 Ensrud KE, Crandall CJ. Osteoporosis. Ann Intern Med 2017;167
(03):ITC17–ITC32
3 Fukumoto S, Matsumoto T. Recent advances in the management
of osteoporosis. F1000 Res 2017;6:625
4 Qaseem A, Forciea MA, McLean RM, Denberg TD; Clinical Guide-
lines Committee of the American College of Physicians. Treatment
of low bone density or osteoporosis to prevent fractures in men
and women: a clinical practice guideline update from the Amer-
ican College of Physicians. Ann Intern Med 2017;166(11):
818–839
5 Kuo TR, Chen CH. Bone biomarker for the clinical assessment
of osteoporosis: recent developments and future perspectives. Bio-
mark Res 2017;5:18
6 Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the
European Union: medical management, epidemiology and eco-
nomic burden. A report prepared in collaboration with the Inter-
national Osteoporosis Foundation (IOF) and the European
Federation of Pharmaceutical Industry Associations (EFPIA). Arch
Osteoporos 2013;8:136
7 Minisola S, Cipriani C, Occhiuto M, Pepe J. New anabolic therapies
for osteoporosis. Intern Emerg Med 2017;12(07):915–921
8 O’Neill TW, Roy DK. How many people develop fractures with what
outcome? Best Pract Res Clin Rheumatol 2005;19(06):
879–895
9 Lorentzon M, Cummings SR. Osteoporosis: the evolution of a
diagnosis. J Intern Med 2015;277(06):650–661
10 Cosman F, de Beur SJ, LeBoff MS, et al: National Osteoporosis
Foundation. Clinician’s guide to prevention and treatment of
osteoporosis. Osteoporos Int 2014;25(10):2359–2381
11 Rossini M, Adami S, Bertoldo F, et al. Guidelines for the diagnosis,
prevention and management of osteoporosis. Reumatismo 2016;
68(01):1–39
12 Management of osteoporosis in postmenopausal women: 2010
position statement of The North American Menopause Society.
Menopause 2010;17(01):25–54, quiz 55–56
13 Ramirez J, Nieto-González JC, Curbelo Rodríguez R, Castañeda S,
Carmona L. Prevalence and risk factors for osteoporosis and
fractures in axial spondyloarthritis: a systematic review and
meta-analysis. Semin Arthritis Rheum 2017;pii:50049-0172(17)
30640-2
14 Tawaratsumida H, Setoguchi T, Arishima Y, et al. Risk factors for
bone loss in patients with rheumatoid arthritis treated with
biologic disease-modifying anti-rheumatic drugs. BMC Res Notes
2017;10(01):765
15 U.S. Preventive Services Task Force. Screening for osteoporosis: U.-
S. Preventive Services Task Force recommendation statement.
Ann Intern Med 2011;154(05):356–364
16 Gourlay ML, Fine JP, Preisser JS, et al; Study of Osteoporotic
Fractures Research Group. Bone-density testing interval and
transition to osteoporosis in older women. N Engl J Med 2012;
366(03):225–233
17 Vazikaran SD. Utility of biochemical markers of bone turnover and
bone mineral density in management of osteoporosis. Crit Rev
Clin Lab Sci 2008;45(02):221–258
18 Kyd PA, Vooght KD, Kerkhoff F, Thomas E, Fairney A. Clinical
usefulness of bone alkaline phosphatase in osteoporosis. Ann Clin
Biochem 1998;35(Pt 6):717–725
19 Kučukalić-Selimović E, Valjevac A, Hadžović-Dživo A. The utility
of procollagen type 1 N-terminal propeptide for the bone status
assessment in postmenopausal women. Bosn J Basic Med Sci
2013;13(04):259–265
20 Nenonen A, Cheng S, Ivaska KK, et al. Serum TRACP 5b is a useful
marker for monitoring alendronate treatment: comparison with
other markers of bone turnover. J Bone Miner Res 2005;20(10):
1804–1812
21 Lee J, Vazikaran S. Current recommendations for laboratory
testing and use of bone turnover markers in management of
osteoporosis. Ann Lab Med 2012;32(02):105–112
22 Kanis JA, Burlet N, Cooper C, et al; European Society for Clinical
and Economic Aspects of Osteoporosis and Osteoarthritis
(ESCEO). European guidance for the diagnosis and management
of osteoporosis in postmenopausal women. Osteoporos Int 2008;
19(04):399–428
23 Vazikaran S, Eastell R, Bruyère O, et al; IOF-IFCC Bone Marker
Standards Working Group. Markers of bone turnover for the
prediction of fracture risk and monitoring of osteoporosis treat-
ment: a need for international reference standards. Osteoporo-
s Int 2011;22(02):391–420
24 O’Neill S, MacLennan A, Bass S, et al; Osteoporosis Australia
Medical Scientific Committee. Guidelines for the manage-
ment of postmenopausal osteoporosis for GPs. Aust Fam Physi-
cian 2004;33(11):910–919
25 Kim SY, Zhang M, Bockman R. Bone mineral density response
from teriparatide in patients with osteoporosis. HSS J 2017;13
(02):171–177
26 Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Regin-
ster JY; Scientific Advisory Board of the European Society for
Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
(ESCEO) and the Committee of Scientific Advisors of the Inter-
national Osteoporosis Foundation (IOF). European guidance for
the diagnosis and management of osteoporosis in postmenopausal
women. Osteoporos Int 2013;24(01):23–57
27 Feldstein AC, Black D, Perrin N, et al. Incidence and demography of
femur fractures with and without atypical features, J Bone Miner
Res 2012;27(05):977–986
28 Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecros-
osis of the jaw. Nat Rev Rheumatol 2011;8(02):90–96
29 Park-Wyllie LYM, Mamdani MM, Juurlink DN, et al. Bisphospho-
rate use and the risk of subtrochanteric or femoral shaft fractures
in older women. JAMA 2011;305(08):783–789
30 Galis B, Zajko J, Hirjak D, et al. Is the prevalence of the medication-
related osteonecrosis of the jaws underestimated, evaluation in
oncological and non-oncological disease. Bratisl Lek Listy (Tla-
cene Vyd) 2017;118(12):724–731
31 Dubois EA, Rissmann R, Cohen AF. Denosumab. Br J Clin Pharma-
col 2011;71(06):804–806
32 Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of
denosumab therapy for osteoporosis: a systematic review and
position statement by ECTS. Bone 2017;105:11–17
33 Pilmane M, Salma-Ancane K, Loca D, Locs J, Berzina-Cimdina L.
Strontium and strontium ranelate: historical review of some of
their functions. Mater Sci Eng C 2017;78:1222–1230
34 Tabatabaei-Malazy O, Salari P, Khashayar P, Larijani B. New
horizons in treatment of osteoporosis. Daru 2017;25(01):2
35 Komm BS, Morgenstern D, A Yamamoto L, Jenkins SN. The safety
and tolerability profile of therapies for the prevention and treat-
ment of osteoporosis in postmenopausal women. Expert Rev Clin
Pharmacol 2015;8(06):769–784
36 Muschitz C, Kocjan R, Fahrleitner-Pammer A, Lung S, Resch H.
Antiresorptives overlapping ongoing teriparatide treatment
result in additional increases in bone mineral density. J Bone
Miner Res 2013;28(01):196–205
37 Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treat-
ment in postmenopausal women with osteoporosis. N Engl J Med
2016;375(16):1532–1543
38 Leder BZ, Tsai JN, Uihlein AV, et al. Two years of denosumab and
teriparatide administration in postmenopausal women with
osteoporosis (The DATA Extension Study): a randomized con-
trolled trial. J Clin Endocrinol Metab 2014;99(05):1694–1700
39 Compston J. The use of combination therapy in the treatment of
postmenopausal osteoporosis. Endocrine 2012;41(01):11–18
40 Cosman F, Wermers RA, Recknor C, et al. Effects of teriparatide in
postmenopausal women with osteoporosis on prior alendronate or
raloxifene: differences between stopping and continuing the anti-
resorptive agent. J Clin Endocrinol Metab 2009;94(10):3772–3780
41 Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide,
alendronate, or both in women with postmenopausal osteopo-
rosis. J Clin Endocrinol Metab 2010;95(04):1838–1845